Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex for IgG Subclass Deficiency
NCT00417573Phase 2Completed
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
- Start
- Dec 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous human immunoglobulin in IgG subclass deficiency (IgGSD), sponsored by The Center for Rheumatic Disease, Allergy, & Immunology. Started Dec 2004; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
IgG subclass deficiency (IgGSD)
Beyond the preview
Go deeper on NCT00417573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417573.